LLY

1,065.38

+0.03%↑

JNJ

208.01

-1.23%↓

ABBV

224.28

-0.28%↓

UNH

331.13

+1.25%↑

AZN

90.81

+0.46%↑

LLY

1,065.38

+0.03%↑

JNJ

208.01

-1.23%↓

ABBV

224.28

-0.28%↓

UNH

331.13

+1.25%↑

AZN

90.81

+0.46%↑

LLY

1,065.38

+0.03%↑

JNJ

208.01

-1.23%↓

ABBV

224.28

-0.28%↓

UNH

331.13

+1.25%↑

AZN

90.81

+0.46%↑

LLY

1,065.38

+0.03%↑

JNJ

208.01

-1.23%↓

ABBV

224.28

-0.28%↓

UNH

331.13

+1.25%↑

AZN

90.81

+0.46%↑

LLY

1,065.38

+0.03%↑

JNJ

208.01

-1.23%↓

ABBV

224.28

-0.28%↓

UNH

331.13

+1.25%↑

AZN

90.81

+0.46%↑

Search

Penumbra Inc

Closed

SectorHealthcare

314.93 1.86

Overview

Share price change

24h

Current

Min

306.71

Max

318.64

Key metrics

By Trading Economics

Income

581K

46M

Sales

15M

355M

P/E

Sector Avg

73.607

76.798

Profit margin

12.927

Employees

4,500

EBITDA

4M

55M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+9.29% upside

Market Stats

By TradingEconomics

Market Cap

3.3B

12B

Previous open

313.07

Previous close

314.93

News Sentiment

By Acuity

50%

50%

167 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Penumbra Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

18 gru 2025, 23:54 UTC

Hot Stocks

Stocks to Watch: Nike, Cassava Sciences, KB Home

18 gru 2025, 23:51 UTC

Earnings

Nike Sales Tick Up in 2Q; China Weakness Persists -- Update

18 gru 2025, 23:39 UTC

Major Market Movers

Cassava Sciences Shares Fall After FDA Places Hold on Epilepsy Drug Trial

18 gru 2025, 22:57 UTC

Acquisitions, Mergers, Takeovers

TikTok Signs Agreement for Sale of U.S. Unit, Axios Reports, Citing a Memo

18 gru 2025, 21:40 UTC

Earnings

Nike Sales Tick Up, But China Weakness Persists

18 gru 2025, 23:45 UTC

Market Talk

Gold Steady, Supported by Fed Rate-Cut Prospects -- Market Talk

18 gru 2025, 23:37 UTC

Market Talk
Earnings

Nike 2Q Results Fail to Convince Investors of Recovery -- Market Talk

18 gru 2025, 23:36 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Rally -- Market Talk

18 gru 2025, 23:03 UTC

Acquisitions, Mergers, Takeovers

Mitsubishi Materials: Impact on Consolidated Results for FY Ending March 2026 Likely to be Immaterial

18 gru 2025, 23:02 UTC

Acquisitions, Mergers, Takeovers

Mitsubishi Materials: To Acquire 4,448 Common Shares, 13,771 Preferred Shares of Co.

18 gru 2025, 23:00 UTC

Acquisitions, Mergers, Takeovers

Mitsubishi Materials: Investment to Strengthen Recovery Network in U.S.

18 gru 2025, 22:59 UTC

Acquisitions, Mergers, Takeovers

Mitsubishi Materials: Investment to Contribute to Expanding Collection Volume of Secondary Raw Material

18 gru 2025, 22:58 UTC

Acquisitions, Mergers, Takeovers

SpaceX Could Go Public by Merging With EchoStar. It Isn't a Crazy Idea. -- Barrons.com

18 gru 2025, 22:57 UTC

Acquisitions, Mergers, Takeovers

Mitsubishi Materials: Elemental USA E-Waste Operates E-Waste Recycling Business in U.S.

18 gru 2025, 22:56 UTC

Acquisitions, Mergers, Takeovers

Mitsubishi Materials: To Acquire Portion of Shares of Elemental USA E-Waste & ITAD

18 gru 2025, 22:55 UTC

Earnings

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 gru 2025, 21:59 UTC

Earnings

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 gru 2025, 21:50 UTC

Market Talk
Earnings

Tech, Media & Telecom Roundup: Market Talk

18 gru 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

18 gru 2025, 21:35 UTC

Earnings

FedEx's Earnings Were Strong. Cost Cuts and Shipment Volume Helped. -- Barrons.com

18 gru 2025, 21:31 UTC

Earnings

Nike Earnings Top Expectations. Why the Stock Is Down. -- Barrons.com

18 gru 2025, 21:15 UTC

Earnings

Nike 2Q Europe, Middle East & Africa Rev $3.39B >NKE

18 gru 2025, 21:15 UTC

Earnings

Nike 2Q Greater China Rev Down 17% >NKE

18 gru 2025, 21:15 UTC

Earnings

Nike 2Q EPS 53c >NKE

18 gru 2025, 21:15 UTC

Earnings

Nike 2Q Apparel Rev $3.91B >NKE

18 gru 2025, 21:15 UTC

Earnings

Nike 2Q Equipment Rev $550M >NKE

18 gru 2025, 21:15 UTC

Earnings

Nike 2Q N Amer Rev $5.63B >NKE

18 gru 2025, 21:15 UTC

Earnings

Nike 2Q Footwear Rev $7.66B >NKE

18 gru 2025, 21:15 UTC

Earnings

Nike 2Q Asia Pacific & Latin America Rev Down 4% >NKE

18 gru 2025, 21:15 UTC

Earnings

Nike 2Q Greater China Rev $1.42B >NKE

Peer Comparison

Price change

Penumbra Inc Forecast

Price Target

By TipRanks

9.29% upside

12 Months Forecast

Average 338 USD  9.29%

High 388 USD

Low 266 USD

Based on 14 Wall Street analysts offering 12 month price targets forPenumbra Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

14 ratings

13

Buy

1

Hold

0

Sell

Technical Score

By Trading Central

288.28 / 292.9394Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Bullish Evidence

Long Term

Weak Bullish Evidence

Sentiment

By Acuity

167 / 374 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Penumbra Inc

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
help-icon Live chat